Manufacturers OEM

The Binding Site GmbH

Robert-Bosch-Str. 2 A , 68723 Schwetzingen
Germany

Telephone +49 6202 9262-0
Fax +49 6202 9262-222
office@bindingsite.de

Trade fair hall

  • Hall 3 / B73
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 3): stand B73

Fairground map

MEDICA 2016 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.11  Controls / Standards / Calibrators clinical chemistry

Controls / Standards / Calibrators clinical chemistry

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.12  Units and systems for clinical chemical determination

Units and systems for clinical chemical determination

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.12  Units and systems for clinical chemical determination
  • 03.01.12.02  Diagnostic agents / kits for clinical chemistry

Diagnostic agents / kits for clinical chemistry

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.12  Units and systems for clinical chemical determination
  • 03.01.12.04  Mechanical units for clinical chemistry

Mechanical units for clinical chemistry

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.12  Units and systems for clinical chemical determination
  • 03.01.12.05  Reagents for clinical chemistry

Reagents for clinical chemistry

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.07  Immuno assay systems

Immuno assay systems

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.07  Immuno assay systems
  • 03.02.07.06  Enzyme immunoassay (EIA, ELISA, EMIT)

Enzyme immunoassay (EIA, ELISA, EMIT)

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.07  Immuno assay systems
  • 03.02.07.20  Radial immunodiffusion (RID), rocket immunoelectrophoresis (electroimmunoassay, Laurell technique)

Radial immunodiffusion (RID), rocket immunoelectrophoresis (electroimmunoassay, Laurell technique)

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.08  Units and systems for the determination of immunoglobulins and plasma proteins

Units and systems for the determination of immunoglobulins and plasma proteins

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.08  Units and systems for the determination of immunoglobulins and plasma proteins
  • 03.02.08.01  Diagnostic agents / kits for immunoglobulin and plasma protein determination

Diagnostic agents / kits for immunoglobulin and plasma protein determination

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.08  Units and systems for the determination of immunoglobulins and plasma proteins
  • 03.02.08.03  Control material for immunoglobulin and plasma protein determination

Control material for immunoglobulin and plasma protein determination

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.08  Units and systems for the determination of immunoglobulins and plasma proteins
  • 03.02.08.04  Nephelometry

Nephelometry

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.08  Units and systems for the determination of immunoglobulins and plasma proteins
  • 03.02.08.05  Reagents for immunoglobulin and plasma protein determination

Reagents for immunoglobulin and plasma protein determination

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.08  Units and systems for the determination of immunoglobulins and plasma proteins
  • 03.02.08.06  Turbidimetry (Units and systems for the determination of immunoglobulins and plasma proteins)

Turbidimetry (Units and systems for the determination of immunoglobulins and plasma proteins)

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.14  Specific proteins

Specific proteins

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.14  Specific proteins
  • 03.02.14.01  C-reactive proteins (CRP)

C-reactive proteins (CRP)

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.17  Tumor markers

Tumor markers

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.17  Tumor markers
  • 03.02.17.01  Diagnostic agents / kits for tumour marker determination

Diagnostic agents / kits for tumour marker determination

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.17  Tumor markers
  • 03.02.17.02  Units and systems for tumour marker determination

Units and systems for tumour marker determination

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.17  Tumor markers
  • 03.02.17.03  Control material for tumour marker determination

Control material for tumour marker determination

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.17  Tumor markers
  • 03.02.17.04  Reagents for tumour marker determination

Reagents for tumour marker determination

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.17  Tumor markers
  • 03.02.17.05  Accessories for tumour marker determination

Accessories for tumour marker determination

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.01  Bacteriology - Infectious immunology

Bacteriology - Infectious immunology

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.04  Controls / Standards / Calibrators - Infect. immunology

Controls / Standards / Calibrators - Infect. immunology

About us

Company details

Binding Site is committed to improving patient lives worldwide through education, collaboration and innovation. This Specialist Protein company focuses on research, development, manufacture and distribution of innovative immuno-diagnostic systems and assays for the global laboratory market.

Based in Birmingham, UK where their products are manufactured, Binding Site supports sales in North America and most of Europe through its 8 offices and by a distributor network in over 80 other countries. Worldwide the company employs around 600 people with over 400 based in Birmingham. Since April 2011 Binding Site has been owned by Nordic Capital Fund VII. With the strategic and financial support of Nordic Capital, Binding Site is further strengthening its position as the world’s leading supplier of IVD systems for identifying and monitoring B-cell dyscrasias and primary immunodeficiency. Turnover for the year to September 2012 was approximately £55 million, an increase of 15% on the previous year[HW1] .

Binding Site manufactures a wide range of high quality innovative products:

OEM. Our experience and expertise in the in-vitro diagnostics market means we can supply the high quality materials, specialist technical support, excellent customer service, bespoke products, reliability and problem-solving approach that our OEM partners need.

Freelite® is a novel and highly significant tumour marker used for the diagnosis, prognosis and monitoring of Multiple Myeloma, a cancer of cells in the bone marrow.

Hevylite®, a new tumour marker complementary to Freelite, is providing clinicians with further information to manage patients with Multiple Myeloma.

Primary Immunodeficiency Diseases (PID). Binding Site is a market leader in the development of products for the investigation of PID (disorders in which part of the body’s immune system is missing or not functioning correctly).

SPAPLUS® is a fully supported, dedicated and reliable protein analyser which complements the specialist Freelite, Hevylite and IgG subclass assays that Binding Site are well-known for, plus a wide range of other protein assays.

More Less

Company data

Sales volume

50-99 Mio US $

Export content

> 75%

Number of employees

500-999

Foundation

1983

Area of business

Diagnostics